Latest News & Features
Generics
A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent. 13 May 2022
Big Pharma
Novartis has convinced a Delaware court that a patent for its flagship multiple sclerosis treatment Gilenya is directed at patent-eligible matter, dismissing a challenge from Handa Pharmaceuticals that the patent is directed at natural phenomena and invalid. 12 May 2022
Big Pharma
The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone. 12 May 2022
Biotechnology
The UK government will implement the Genetic Technology Bill which promises to “remove unnecessary barriers” inherited from the European Union to bolster gene-editing technology. 11 May 2022
Biotechnology
Canadian pharmaceutical company GlycoBioSciences has sued cosmetics giant L’Oreal, alleging that the French company’s anti-wrinkle products containing hyaluronic acid infringe two patents. 10 May 2022
Americas
Moderna has rejected claims that its COVID-19 vaccine violates the patent rights of two biopharma companies, arguing that its contract with the US federal government has conferred immunity. 10 May 2022
Asia
Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents. 9 May 2022
Big Pharma
Harvard College and 10x Genomics have sued Vizgen, claiming that the Massachusetts-based biotech rival infringes five patents covering molecular analysis methods. 5 May 2022
article
A proposal for the COVID-19 vaccine waiver has been prepared for approval by the wider members of the World Trade Organisation. 5 May 2022
Big Pharma
Two subsidiaries of Ireland-based Jazz Pharmaceuticals have failed in their bid to challenge the jurisdiction of the English High Court in a dispute with Tokyo-headquartered Otsuka Pharmaceutical over a cannabis sativa collaboration. 4 May 2022